SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation S9333A

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia.

NCT00899743 Leukemia Genetic: polyacrylamide gel electrophoresis Genetic: western blotting Other: immunologic technique Other: laboratory biomarker analysis
MeSH:Leukemia
HPO:Leukemia

S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. --- S9333A ---

Primary Outcomes

Measure: Association of specific clinicopathological variables and outcomes with calmodulin-dependent protein kinase II-╬│ (CaMKII╬│) activation (autophosphorylation)

Time: upon receipt of specimens


HPO Nodes